Cited by 1,015Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis

Open access
Stine, W. Blaine, Dahlgren, Karie N., Krafft, Grant A., LaDu, Mary Jo·2003·Journal of Biological Chemistry

Abstract

Extensive research causally links amyloid-beta peptide (A beta) to Alzheimer's disease, although the pathologically relevant A beta conformation remains unclear. A beta spontaneously aggregates into the fibrils that deposit in senile plaques. However, recent in vivo and in vitro reports describe a potent biological activity for oligomeric assemblies of A beta. To consistently prepare in vitro oligomeric and fibrillar forms of A beta 1-42, a detailed knowledge of how solution parameters influence structure is required. This manuscript represents the first study using a single chemically and structurally homogeneous unaggregated starting material to demonstrate that the formation of oligomers, fibrils, and fibrillar aggregates is determined by time, concentration, temperature, pH, ionic strength, and A beta species. We recently reported that oligomers inhibit neuronal viability 10-fold more than fibrils and approximately 40-fold more than unaggregated peptide, with oligomeric A beta 1-42-induced neurotoxicity significant at 10 nm. In addition, we were able to differentiate by structure and neurotoxic activity wild-type A beta1-42 from isoforms containing familial mutations (Dahlgren, K. N., Manelli, A. M., Stine, W. B., Jr., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) J. Biol. Chem. 277, 32046-32053). Understanding the biological role of specific A beta conformations may define the link between A beta and Alzheimer's disease, re-focusing therapeutic approaches by identifying the pernicious species of A beta ultimately responsible for the cognitive dysfunction that defines the disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m210207200

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The 48 h total incubation leads to mature Aβ42 fibrils, as observed by TEM, while the Western blot shows the presence of higher order Aβ42 oligomers, likely due to an assembly-disassembly equilibrium that is established for mature Aβ fibrils.

    “The 48 h total incubation leads to mature Aβ42 fibrils, as observed by TEM (Figure 10, panel a) while the Western blot shows the presence of higher order Aβ42 oligomers (Figure 10, lane a), likely due to an assembly-disassembly equilibrium that is established for mature Aβ fibrils.89–91”

    From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ<sub>42</sub>Peptide (2012) · cites this paper as [91]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • The MOAB-2-based oAβ42 ELISA detects oligomeric but not monomeric Aβ42.

    “In addition, the MOAB-2-based oA␤42 ELISA detects oligomeric but not monomeric A␤42 using synthetic preparations characterized previously by our laboratory (data not shown) (47,48).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., and Mucke, L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3228 -3233
  2. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Proc. Natl. Acad. Sci.
  3. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 571-576
  4. Lomakin, A., Chung, D., Benedek, G., Kirschner, D., and Teplow, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1125-1129
  5. Kusumoto, Y., Lomakin, A., Teplow, D. B., and Benedek, G. B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12277-12282
  6. Lorenzo, A., and Yankner, B. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12243-12247
  7. Kowalewski, T., and Holtzman, D. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3688 -3693
  8. Solomon, B., Koppel, R., Frankel, D., and Hanan-Aharon, E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4109 -4112

Cited by

Sorted by citations

Authors
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J.
Affiliations
Northwestern University (US)
Corresponding author
LaDu, Mary Jo
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2003-03
Volume
278
Issue
13
Pages
11612-11622
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2133631618
Cited by
1,015
References
74
Citations by year
2026: 40 · 2025: 39 · 2024: 37 · 2023: 39 · 2022: 34 · 2021: 49 · 2020: 37 · 2019: 40 · 2018: 33 · 2017: 46 · 2016: 49 · 2015: 42 · 2014: 60 · 2013: 52 · 2012: 69
FWCI
19.08
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • Northwestern University
  • National Institutes of Health (1p01ag015501-01, 5r01ag013496-05)
  • National Institute on Aging (R01AG019121, AG-15501, AG 19121, AG13496)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, amyloid-beta 42, oligomerization, fibril formation, Alzheimer's disease, neurotoxicity, peptide aggregation, solution conditions, familial Alzheimer's disease mutations, amyloid plaques, peptide conformation
MeSH terms
Biopolymers, Circular Dichroism, Electrophoresis, Polyacrylamide Gel, Peptide Fragments, Solubility, Blotting, Western, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review